Clinical Trials Logo

Cysticercosis clinical trials

View clinical trials related to Cysticercosis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02947581 Terminated - Neurocysticercosis Clinical Trials

Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)

SANTO
Start date: November 14, 2016
Phase: Phase 3
Study type: Interventional

Taenia solium neurocysticercosis (NCC) is a parasitic infection causing much neurological disease in most of the world. When parasites locate in the cavities around the brain (subarachnoid NCC, SANCC), it becomes an aggressive, progressive and frequently lethal presentation. Current treatment regimens for SANCC have quite limited efficacy. The investigators propose to compare the current standard of care (a single antiparasitic drug, albendazole) with a combined regimen using two antiparasitic drugs simultaneously by adding praziquantel. The trial will enrol 164 patients in four centers, two in Peru, one in Ecuador, and one in Brasil.

NCT ID: NCT02945527 Terminated - Neurocysticercosis Clinical Trials

Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)

Start date: December 4, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Three-arm open, randomized comparative study of acetazolamide, dexamethasone, or no additional treatment to evaluate decrease in peri-calcification edema in neurocysticercosis

NCT ID: NCT02233855 Terminated - Neurocysticercosis Clinical Trials

People Presenting With Neurocysticercosis in North America

Start date: September 3, 2014
Phase:
Study type: Observational

Background: - Neurocysticercosis (NCC) is caused by tapeworms that infect people. NCC can lead to serious brain problems such as seizures, sevre headaches and difficulties with movements or sensation in the limbs. Researchers want to learn more about the different ways in which people in the United States present with this disease and how they respond to standard and newer treatments. Objective: - To learn about the different forms of NCC that occurs throughout North America and how patients with these forms respond to treatment. Eligibility: - Adults age 18 or older with NCC. Design: - Participants will be screened with: - Medical history and physical exam. - A computed tomography (CT) brain scan The participant will lie still on a table that slides into a large donut-shaped scanner. - Blood drawn through an arm vein for analysis - A magnetic resonance imaging (MRI) scan of the brain and spine. They will lay flat in a long metal cylinder as the machine makes images of the body. During the scan, participants will receive a contrast agent through an IV that allows high resolution imaging of the brain and spine - Participants will visit the clinic at 0, 1, 2, 3, 6, 12, and 24 months (7 times), and depending on the need for monitoring, more times. Participants will receive a schedule that will explain the procedures done at each visit. - At these visits, participants may: - Repeat the screening procedures. - Be asked about their NCC symptoms and their physical and mental health. - Have a urine test. - Take a test of their ability to concentrate, their memory and spatial recognition. - Have a lumbar puncture, if indicated by the state and severity of infection. A needle will be inserted through the skin and into the space between the bones in the back. Cerebrospinal fluid will be removed.